A second TriNetXcomparative study involving more than 640,000 patients with T2D and non-alcoholicfatty liver disease (NAFLD) showed that semaglutide was associated with asignificantly lower risk of major adverse liver outcomes, including decompensatedcirrhosis, hepatocellular carcinoma, and liver transplantation, compared withSGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, andthiazolidinediones, and also conferred a survival advantage [166]. The gene discussed is DPP4; the disease is metabolic dysfunction-associated steatotic liver disease.